Stockrabit · Analysts
Questions across 2 calls

Ravi Purohit

Firm not listed in source transcripts

GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited CC-Dec24.pdf · 2025-02-14
Yes, hi. First of all, congratulations, Mr. Akshikar. I think you have been one of the few MDs of this company, who when you joined the company, I think, put out in your communication to investors in the annual report that you will be targeting double-digit sales growth. And the first nine months is kind of an indication of that, I think, and hopefully we will be able to kind of, you know, maintain this growth momentum. So, you know, Sir , if you could kind of give us some sense about what other areas are we looking at to kind of drive double -digit growth over the medium term, right? You mentioned about Nucala and Trelegy, of course. But are there more products in the pipeline? And of course, you also mentioned about these two cancer drugs, but is there more in the pipeline that we are looking at working with or are we also at the same time looking at inorganic opportunities or in- licensing opportunities? So, if you could just ki nd of provide a medium -term path as to how you visuali se, you know, growth is coming for our company. And also if you could spend some time on, you know, things or initiatives that we might have taken on the general medicines side, because that has also shown pretty strong volume growth. Is it because of Ceftum or some of the products which had taken severe price knocks last year and then NLEM , they have started kind of showing volume growth. So, if you could kind of, you know, highlight each of these aspects in a slightly more detailed manner, it would be helpful for us. We get like four times in a year to kind of hear you.
Great, thanks a lot. And Sir, another thing is, if we look at the overall pharmacy market in India, right, so various estimates put out the number of pharmacies in the country between, let's say, 6 lakhs to 9 lakhs, right. In that sense, is there any opportunity for us to kind of imp rove our penetration in that network yet? Or would you say that we are well penetrated across outside of metros and tier 1 and tier 2 and penetration across our brand portfolio is fairly saturated or would you think there is opportunity for us to kind of expand there?
GlaxoSmithKline Pharmaceuticals Limited CC-Dec23.pdf · 2024-02-15
Thanks a lot for doing this Analysts' Meet. So, Mr. Bhushan, I have a couple of questions. I think in your annual report, the first message as the MD of this company, you have mentioned about this double-digit sales growth target. You have again reiterated that today in the presentation. If you look at our company's history over the last 10 years, there has not been a single year when we have experienced double-digit sales growth. So, you know, it's great to hear this, right? And we are already like shareholders of our company. But if you could just elaborate a little bit, what is the path that will result in us kind of getting this double-digit sales growth? What are the things, what are the steps that we are doing? And we already had brands, but we had these brands earlier as well, right? So, what is changing now? And what are the changes that you are bringing in? Is it going to be new product launches? Is it going to be existing products? Is it going to be existing products reaching a wider customer base? So, if you could add some more color to this ambition of growing double digit, right? Because Glaxo has not done that in a long, long time when practically all investors have forgotten that Glaxo could actually grow, right? So, it would be great if you could change that perspective and give us some insight into that. And my second question is on the vaccines that I think you have mentioned a lot in our presentation as well as in our annual report about vaccines. But vaccines essentially is a traded good for us, right? We import from Europe. How does a faster growing vaccines portfolio affect our margins in the long term? Because we also mentioned about maintaining or improving our margins. So, can the two coexist? Those are my two questions. Thank you.